Literature DB >> 23160385

Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer.

Sokratis Trellakis1, Kirsten Bruderek, Jan Hütte, Motaz Elian, Thomas K Hoffmann, Stephan Lang, Sven Brandau.   

Abstract

Granulocytic myeloid-derived suppressor cells (MDSC) are a MDSC subset expanded in various cancer types. As many clinical studies rely on the use of stored collections of frozen blood samples, we first tested the influence of freezing/thawing procedures on immunophenotyping and enumeration of granulocytic MDSC (G-MDSC). To identify factors involved in expansion of human G-MDSC, we then analyzed correlations between G-MDSC frequencies, clinical parameters and granulocyte-related factors in the peripheral blood of head and neck cancer patients. HLA-DR, CD14, CD33 and CD66b allowed a clear discrimination of G-MDSC from monocytic MDSC and immature myeloid cells. MDSC subsets were sensitive to cryopreservation with immature G-MDSC showing the highest sensitivity. G-MDSC frequencies were increased in advanced disease stage and associated with the level of CCL4 and CXCL8, but not with colony-stimulating factors, IL-6, S100A8/9, CXCL1 and other cytokines. Our results indicate that the frequency of MDSC, in particular G-MDSC, may be underestimated in retrospective clinical analyses using frozen blood samples. Increased G-MDSC frequencies correlate with advanced disease and increased concentrations of CXCL8, but, unexpectedly, not with growth factors (such as granulocyte colony-stimulating factor), IL-6 and CXCL1. Our data suggest that CXCL8 promotes accumulation of G-MDSC in cancer patients independent of classical colony-stimulating factors.

Entities:  

Keywords:  CXCL8; Cryopreservation; granulocyte-colony stimulating factor; granulocyte-macrophage-colony stimulating factor; immune monitoring; peripheral blood

Mesh:

Substances:

Year:  2012        PMID: 23160385     DOI: 10.1177/1753425912463618

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  48 in total

1.  Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Authors:  Amy W Ku; Jason B Muhitch; Colin A Powers; Michael Diehl; Minhyung Kim; Daniel T Fisher; Anand P Sharda; Virginia K Clements; Kieran O'Loughlin; Hans Minderman; Michelle N Messmer; Jing Ma; Joseph J Skitzki; Douglas A Steeber; Bruce Walcheck; Suzanne Ostrand-Rosenberg; Scott I Abrams; Sharon S Evans
Journal:  Elife       Date:  2016-12-08       Impact factor: 8.140

2.  Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Authors:  Steven L Highfill; Yongzhi Cui; Amber J Giles; Jillian P Smith; Hua Zhang; Elizabeth Morse; Rosandra N Kaplan; Crystal L Mackall
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

3.  Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption.

Authors:  Sandra E Dross; Paul V Munson; Se Eun Kim; Debra L Bratt; Hillary C Tunggal; Ana L Gervassi; Deborah H Fuller; Helen Horton
Journal:  J Immunol       Date:  2016-12-14       Impact factor: 5.422

4.  Targeting STAT3 signaling reduces immunosuppressive myeloid cells in head and neck squamous cell carcinoma.

Authors:  Lin-Lin Bu; Guang-Tao Yu; Wei-Wei Deng; Liang Mao; Jian-Feng Liu; Si-Rui Ma; Teng-Fei Fan; Bradford Hall; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

Review 5.  Role of myeloid-derived suppressor cells in metastasis.

Authors:  Kathryn Cole; Kristina Pravoverov; James E Talmadge
Journal:  Cancer Metastasis Rev       Date:  2021-01-07       Impact factor: 9.264

Review 6.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

7.  CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Lin-Lin Bu; Yu-Yue Zhao; Liang Mao; Wei-Wei Deng; Tian-Fu Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

8.  Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.

Authors:  Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

Review 9.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

10.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.